KR20030056582A - Composition for immune enhancement - Google Patents

Composition for immune enhancement Download PDF

Info

Publication number
KR20030056582A
KR20030056582A KR1020010086846A KR20010086846A KR20030056582A KR 20030056582 A KR20030056582 A KR 20030056582A KR 1020010086846 A KR1020010086846 A KR 1020010086846A KR 20010086846 A KR20010086846 A KR 20010086846A KR 20030056582 A KR20030056582 A KR 20030056582A
Authority
KR
South Korea
Prior art keywords
composition
yeast
present
extract
rice
Prior art date
Application number
KR1020010086846A
Other languages
Korean (ko)
Other versions
KR100443401B1 (en
Inventor
김형민
홍승헌
Original Assignee
김형민
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김형민 filed Critical 김형민
Priority to KR10-2001-0086846A priority Critical patent/KR100443401B1/en
Publication of KR20030056582A publication Critical patent/KR20030056582A/en
Application granted granted Critical
Publication of KR100443401B1 publication Critical patent/KR100443401B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535Perilla (beefsteak plant)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/72Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725Ziziphus, e.g. jujube
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9068Zingiber, e.g. garden ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/19Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: An immunostimulating composition containing a natural herbal extract increasing effect on the production of interleukin-2 and interferon-γ and inhibiting secretion of histamine is provided. Therefore, the composition can be effectively used as an agent for or an adjunct to treatment of diseases according to the lowering of immunity, in particular, cold. CONSTITUTION: An immunostimulating composition contains an extract of Glycyrrhizae Radix, Zizyphi Fructus, Pyrus pyrifolia(Burm. fil.) Nakai var. culta (Makino) Nakai, Atractylodis rhizoma alba, Zingiberis Rhizoma, Folium Perillae, Astragali Radix and green onion, Allium fistulosum L. in a weight ratio of 1 to 4:1 to 4: to 10 to 40:3 to 9:1 to 4:1 to 4:2 to 6:5 to 10. The herbal extract is added with a mixture of rice, malted rice and yeast in a ratio of 1 to 4:0.2 to 1:0 to 0.1. and then fermented to produce the immunostimulating composition.

Description

면역 증강용 조성물{Composition for immune enhancement}Composition for immune enhancement

본 발명은 감기 예방 등의 효과를 갖는 면역 증강용 조성물에 관한 것이다. 보다 상세하게는, 본 발명은 유효성분으로서 감초, 대추, 배, 백출, 생강, 소엽, 진피 및 총백의 추출물을 함유하는 면역력 증강용 조성물에 관한 것이다.The present invention relates to an immune enhancing composition having effects such as cold prevention. More specifically, the present invention relates to a composition for enhancing immunity containing extracts of licorice, jujube, pear, baekchul, ginger, lobule, dermis, and baekbaek as an active ingredient.

감기는 일차적인 건강관리에 있어서 가장 빈번하게 치료 및 상담을 요하는 질환이다. 일반 내과 병원을 찾는 환자의 3분의 1 내지 4분의 1 정도가 이른바 감기라 불리는 급성 상기도 감염환자들이다. 소아과 기도 감염은 특히 심각하며 생명을 위협할 수도 있다. 5세 이하의 어린이에 있어서 기도 감염은 폐 질환으로 인해 사망케 하는 가장 중요한 원인으로 알려져 있다. 이와 같은 감염성 질환은 면역기능이 결정적인 역할을 한다. 따라서 면역력 증가는 감기의 예방과 치료에 좋은 수단이 될 수 있다.Colds are the most frequently treated diseases in primary health care. About a third to a quarter of patients who visit general hospitals are acute upper respiratory tract infections called colds. Pediatric airway infections are particularly serious and can be life threatening. In children under five, airway infections are known to be the most important cause of death from lung disease. Infectious diseases such as these play an important role in immune function. Therefore, increased immunity can be a good way to prevent and treat colds.

근래 감기 예방 및 치료를 위한 대체 의약품 시장은 급격히 성장하고 있는데 미국이 경우 전 인구의 약 1/3이 백신과 화학약품이 아닌 대체 의약품에 의존하고 있으며, 유럽에서는 그 비중이 더 큰 것으로 조사되고 있다. 이러한 추세에 비추어 한약과 같은 대체 의약품으로서 면역기능을 증가시키는 효과를 갖는 의약 또는 식품 조성물의 개발이 절실히 요구된다.In recent years, the market for alternative medicine for the prevention and treatment of colds is growing rapidly. In the United States, about one-third of the population relies on alternative medicines, not vaccines and chemicals. . In light of this trend, there is an urgent need for the development of a medicine or a food composition having an effect of increasing immune function as an alternative medicine such as herbal medicine.

면역계는 자연저항, 비특이성 면역체계 및 특이성 면역체계로 구분할 수 있다. 자연저항(1차방어선)이란 미생물을 위시한 모든 침입자들을 그들의 종류에 관계없이 막아내는 해부생리학적 요소들을 말하며, 비특이적 면역(2차방어선)은 자연저항을 돌파하여 체내로 들어온 침입자들을 제거하는 식세포로 구성된 방어체계를, 그리고 특이성 면역계(3차방어선)는 림프구들로 구성된 면역체계를 말하는데, 이중 특이성 면역계는 기억능 그리고 자기와 비자기를 구분할 수 있는 능력을 지닌 고도로 발달한 면역체계이다.The immune system can be divided into natural resistance, nonspecific immune system and specific immune system. Natural resistance (primary defense) refers to anatomical physiological elements that block all invaders, including microorganisms, regardless of their type. Nonspecific immunity (secondary defense) is a phagocyte that breaks through natural resistance and removes invaders. The constructed defense system, and the specific immune system (tertiary line of defense) refer to the immune system composed of lymphocytes, which are highly developed immune systems with memory and the ability to distinguish between self and nonmagnetic.

백혈구는 2차 또는 3차 방어선을 구성하여 1차 방어선을 돌파하여 체내에 들어온 이물을 담당한다. 이중 대식세포는 많은 라이소솜을 가지고 있고 이들은 산성가수분해효소와 과산화 효소를 함유하고 있다. 또한 유리면과 플라스틱 표면에 강하게 부착하는 성질이 있으며 미생물이나 종양세포 등을 활발하게 탐식한다. 이 세포는 IFN-γ등의 싸이토카인 수용체를 가지고 있다. 이들은 보체성분, 인터페론, 인터루킨-1 및 종양괴사인자 같은 싸이토카인을 생산하며 T-세포로부터 생산되는 여러 가지 싸이토카인에 의해 기능이 증강될 수 있다.Leukocytes constitute a secondary or tertiary line of defense, breaking through the primary line of defense, and are responsible for foreign bodies entering the body. Macrophages contain many lysosomes, which contain acidic hydrolase and peroxidase. In addition, it strongly adheres to the glass surface and plastic surface, and actively detects microorganisms and tumor cells. This cell has cytokine receptors such as IFN-γ. They produce cytokines such as complement, interferon, interleukin-1 and tumor necrosis factor and can be enhanced by several cytokines produced from T-cells.

역시 백혈구의 일종인 T-세포는 혈중 소림프구의 약 70%를 차지한다. T-세포는 흉선에서 분화되며 T-세포항원수용체(TCR)를 갖는다. 말초혈액 T-세포는 CD4 양성인 TH세포(helper T-cell)와 CD8 양성인 TC 세포(cytotoxic T-cell)로 나뉜다. CD4+TH세포는 MHC classII 분자에 결합된 항원을 인식하여 활성화되며, B세포를 도와서 항체생성을 가능하게 하거나 다른 T 세포의 기능을 돕는다. CD4+TH세포는 다시 그들이 생산하는 싸이토카인을 근거로 TH1 및 TH2로 분류할 수 있다. 실험용 생쥐(mouse)의 TH1세포는 인터루킨-2(IL-2), 인터페론-감마(IFN-γ) 등을 분비하는 반면에 TH2 세포는 IL-4, IL-5, IL-6, IL-9, IL-10, IL-13 등을 분비한다. 그러나 사람에 있어서는 IL-2, IL-6, IL-10, IL-13의 생성이 엄격히 구분되지 않는다. 그외에 IL-3, 종양괴사인자-알파(TNF-α), GM-CSF(granulocyte-macrophage colony-stimulating factor), (메트)엔케팔린[(Met)enkephalin], 키모카인(chemokine, CK) 등도 구분없이 공통으로 분비된다. TH1세포는 세포면역반응에 관여하며 세포독성 및 염증성 반응을 활성화한다. TH2 세포에서 생성된 사이토카인은 항체형성을 촉진시키는데, 특히 IgE의 생성을 도우며 호산구의 증식과 기능을 증강시킨다. 그러므로 TH2 사이토카인은 항체생성 및 알레르기 반응에서 흔히 발견된다. TH1 과 TH2 사이토카인은 서로간에 억제기능을 가지고 있고, 동물의 감염증에서 항 IL-4 항체와 항IFN-γ항체로 질환의 경과를 변화시킬 수 있음이 밝혀졌으며, 류마티스 관절염의 환자에 IFN-γ를 주사하여 증상의 호전이 관찰된 예도 있다.T-cells, also a type of white blood cell, make up about 70% of blood lymphocytes. T-cells differentiate in the thymus and have a T-cell antigen receptor (TCR). Peripheral blood T- cell is divided into CD4-positive T H cells (helper T-cell) and CD8-positive TC cells (cytotoxic T-cell). CD4 + T H cells are activated by recognizing antigens bound to MHC class II molecules, helping B cells to produce antibodies or to help other T cells function. CD4 + T H cells can again be classified into T H 1 and T H 2 based on the cytokines they produce. T H 1 cells in mice secrete interleukin-2 (IL-2), interferon-gamma (IFN-γ), etc., whereas T H 2 cells produce IL-4, IL-5, IL-6 Secrete IL-9, IL-10, IL-13 and the like. However, in humans, the production of IL-2, IL-6, IL-10 and IL-13 is not strictly distinguished. In addition, IL-3, tumor necrosis factor-alpha (TNF-α), granulocyte-macrophage colony-stimulating factor (GM-CSF), (meth) enkephalin (chem) and chemokine (CK) are also distinguished. Are commonly secreted. T H 1 cells are involved in cellular immune responses and activate cytotoxic and inflammatory responses. Cytokines produced in T H 2 cells promote antibody formation, particularly the production of IgE and enhance the proliferation and function of eosinophils. Therefore T H 2 cytokines are commonly found in antibody production and allergic reactions. It has been shown that T H 1 and T H 2 cytokines have mutually inhibitory functions and that the disease progression can be altered with anti-IL-4 and anti-IFN-γ antibodies in animal infections. In some cases, improvement of symptoms was observed by injecting IFN-γ.

이상에서 살펴본 바와 같이, 인터루킨-2(IL-2)나 인터페론-감마(IFN-γ) 등의 생성능력이 탁월한 물질은 면역증강효과가 기대되고, 나아가 그에 따른 감기 예방이나 초기 감기의 치료에 도움이 될 것으로 기대된다.As described above, substances having excellent production ability such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ) are expected to have an immune enhancing effect, and further help in preventing cold or treating early cold. It is expected to be.

본 발명의 목적은 부작용이 없는 천연물을 성분으로 하는 약학적으로 허용 가능한 조성물의 항히스타민 효과, IL-2 및 인터페론-감마 생성능력을 규명함으로써, 감기예방 및 초기 감기 치료효과 등의 효과가 있는 면역 증강용 조성물을 제공하는 것이다.An object of the present invention is to identify the antihistamine effect, IL-2 and interferon-gamma-producing ability of pharmaceutically acceptable compositions containing natural products with no side effects, thereby enhancing immunity such as cold prevention and early cold treatment effects. It is to provide a composition for.

도 1은 본 발명에 따른 조성물에 대한 인터페론-감마 생성 증가 효과를 나타낸 것이고,Figure 1 shows the effect of increasing interferon-gamma production for the composition according to the present invention,

도 2는 본 발명에 따른 조성물에 대한 비만세포에 대한 히스타민 분비 억제 효과를 나타낸 것이다.Figure 2 shows the histamine secretion inhibitory effect on mast cells for the composition according to the present invention.

본 발명은 감초, 대추, 배, 백출, 생강, 소엽, 진피 및 총백의 추출물을 함유하는 면역 증강용 조성물을 제공한다.The present invention provides an immune enhancing composition containing extracts of licorice, jujube, pear, baekchul, ginger, lobule, dermis and baekbaek.

상기 추출 용매로는 물 또는 통상의 유기용매, 예컨대, 메탄올, 에탄올, 프로판올 등이 사용될 수 있으며, 바람직하게는 물이 사용된다. 또한 맛의 향상을 위해 흑설탕 등의 감미제를 첨가할 수 있다.As the extraction solvent, water or a conventional organic solvent such as methanol, ethanol, propanol, and the like may be used, and preferably water is used. In addition, sweeteners such as brown sugar may be added to improve taste.

본 발명의 조성물이 유효한 질환은 특히, 허약체질, 면역능 저하, 초기감기 등일 수 있다.The disease in which the composition of the present invention is effective may be, in particular, weak constitution, lowering immunity, initial cold, and the like.

본 발명에 따른 조성물에서, 감초, 대추, 배, 백출, 생강, 소엽, 진피 및 총백이 1∼4 : 1∼4 : 10∼40 : 3∼9 : 1∼4 : 1∼4 : 2∼6 : 5∼10의 중량비로 혼합된 것이 바람직하다. 또한 상기 조성물에 추가로 흑설탕을 1∼4의 중량비로 혼합할 수 있다.In the composition according to the present invention, licorice, jujube, pear, baekchul, ginger, lobule, dermis, and ginseng are 1-4: 1-4: 10-40: 3-9: 1-4: 1-4: 2-6 It is preferable to mix at a weight ratio of 5-10. In addition to the above composition, brown sugar may be mixed in a weight ratio of 1 to 4.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명에 따른 조성물의 제1 유효성분인 감초(Glycyrrhiza uralensisFISCH)는 다년생 초본인 감초의 근과 근상경이다. 본품은 보비익기, 청열해독, 윤폐지해, 조화제약의 작용을 한다. 본품은 여러 약을 조화시켜 약물의 준열한 성질을 완화시킨다.Licorice ( Glycyrrhiza uralensis FISCH), the first active ingredient of the composition according to the present invention, is a perennial herb and muscles of the licorice. This product plays the role of Bobi ripening, clear heat detoxification, decontamination, harmonious pharmaceuticals. This product harmonizes several drugs to relieve the mild properties of the drug.

본 발명에 따른 조성물의 제2 유효성분인 대추 (Zizyphus jujubaMill. varinermis(Bunge) Rehd)는 갈매나무과에 속한 낙엽관목 혹은 소교목인 대추나무의 성숙한 과실이다. 본품은 보비화위, 익기생진, 안신 등의 효능이 있다.Jujube ( Zizyphus jujuba Mill. Var inermis (Bunge) Rehd), the second active ingredient of the composition according to the present invention, is a mature fruit of the jujube tree, which is a deciduous shrub or sub-tree. This product has the effects of Bobihwawi, pterosaur, anxin.

본 발명에 따른 조성물의 제3 유효성분인 배 (Pyrus pyrifoliavar.culta(Makino) Nakai)는 장미과(Rosaceae)에 속하는 낙엽 교목 또는 관목성 식물인 배나무의 성숙한 과실이다. 본품은 무기성분으로 칼슘, 나트륨, 마그네슘의 함량이 74%을 차지하고, 인이나 유산 등의 함량이 25% 정도로서 강한 알칼리성 식품이므로 배나 배가공품을 많이 먹는 것은 우리 혈액을 중성으로 유지시켜 건강을 유지하는데 큰 효과가 있다. 배에 함유된 비타민의 종류는 다른 과실에 비하여 많은 것은 아니나, 사과에 비하여 비타민 B1, B2 함량은 다소 많고, 비타민 C의 함량은 적다. 비타민 C는 잎에서 동화작용의 결과 생성된 포도당에 의하여 만들어져 이것이 과실 중으로 이동하여 축적되는 것으로 알려져 있는데, 일반적으로 햇빛이 비타민 C 생성에 많은 영향을 주어 햇빛을 많이 받을 과실일수록 비타민 C의 함량이 많다. 가래가 심한 천식이나 어린아이의 기침, 백일해 등에 활용하면 효과적이다. 배의 성질은 냉하나 소화에 효과가 있고, 대변이나 소변을 잘나오게 하여 몸에 열을 내리게 한다. 갈증이 심하거나 심한 숙취에는 배가 간장 활동을 촉진시켜 체내의 알콜성분을 빨리 해독시키므로 주독이 풀어지고 갈증도 없어진다. Pyrus pyrifolia var. Culta (Makino) Nakai, the third active ingredient of the composition according to the present invention, is a mature fruit of a deciduous arborescent or shrub plant belonging to the Rosaceae family. This product is an inorganic ingredient that contains 74% of calcium, sodium, and magnesium, and 25% of phosphorus and lactic acid, which is a strong alkaline food, so eating a lot of pears or processed foods keeps our blood neutral to maintain health. It has a big effect. The type of vitamins contained in the pear is not much higher than other fruits, but the vitamin B1 and B2 content is slightly higher than the apples, and the vitamin C content is low. Vitamin C is made from glucose produced by assimilation in leaves, which is known to accumulate in the fruit. In general, the amount of vitamin C is higher in the sunlight, which affects the production of vitamin C. . It is effective to use sputum with severe asthma, coughing of young children and whooping cough. The nature of the belly is cold, but effective in digestion, the feces or urine will come out to make the body heat. In the case of severe thirst or severe hangovers, the stomach stimulates liver activity to quickly detoxify the alcohol in the body, so the poison is quenched and thirst is eliminated.

본 발명에 따른 조성물의 제4 유효성분인 백출 (Atractylodes macrocephalaKoidz) 은 국화과에 속한 다년생 초본인 흰삽주 및 동속 근연식물의 괴근이다. 본 품은 보비익기, 조습이수, 고표지한 등의 효능을 지닌다. 수습의 정류로 인한 종만 등의 증에 응용한다. 또한 고표지한하는 작용이 있으므로 표허로인한 자한에 응용할 수 있다. Atractylodes macrocephala Koidz, the fourth active ingredient of the composition according to the present invention, is a perennial herb perennial herb of the Asteraceae family and the root of the same plant. This product has the effects of Bobi ripening, humidity control, high labeling. Applied to symptoms such as obesity caused by rectification of probation. In addition, since it has a high labeling effect, it can be applied to the deadline due to the license.

본 발명에 따른 조성물의 제5 유효성분인 생강 (Zingiber offininaleRosc)은 생강과에 속한 다년생 초본인 생강의 신선한 근경이다. 본품은 발한해표, 온중지구, 온폐지해의 효능을 갖는다. 감모풍한이나 비위허한의 증 등에 활용한다.Ginger ( Zingiber offininale Rosc), the fifth active ingredient of the composition according to the present invention, is a fresh root of ginger, which is a perennial herb belonging to the family Ginger. This article has the effect of sweat sweating, warm earth district, the warming of the sea. It is used for the increase of feelings of admiration and the unauthorized.

본 발명에 따른 조성물의 제6 유효성분인 소엽 (Perilla frutescens(L.) var.acuta(Thunb.) Kudo) 은 순형과에 속한 1년생 초본인 차조기의 잎 또는 전초이다. 본품은 발한해표, 행기관중, 해어독 등의 효능이 있다. 감모풍한의 표증, 해수 흉민의 증 등에 활용한다.The sixth active ingredient ( Perilla frutescens (L.) var. Acuta (Thunb.) Kudo) of the composition according to the present invention is a leaf or an outpost of perennial herb, which is a herbaceous herb belonging to the genus. This article has the efficacy of sweat sweating, affairs, seafish poison. It is utilized for indications of sensation of wind, symptom of seawater rash.

본 발명에 따른 조성물의 제7 유효성분인 진피 (Citrus unshiuMarcor) 는 운향과에 속한 상록소교목인 귤나무 및 동속 근연식물의 성숙한 과피이다. 본품은 이기건비, 조습화담 등의 효능이 있다. 비위의 기체병증이나 기역해천 등의 증을 다스린다. Citrus unshiu Marcor, the seventh active ingredient of the composition according to the present invention, is a mature rind of the evergreen cultivars of tangerine and related plants. This product has the effects of ego-gun dry, moist painting. Treats gastrointestinal gastropathy or gastrointestinal symptoms.

본 발명에 따른 조성물의 제8 유효성분인 총백 (Allium fistulosum L.)은 백합과에 속한 다년생 초본인 파의 인경이다. 본품은 해표산한, 통양 등의 효능이 있다. 외감풍한으로 인한 두통 오한, 발열 등의 증을 다스린다.The eighth active ingredient (Allium fistulosum L.) of the composition according to the present invention is a perennial herb, which belongs to the family Liliaceae. This article has efficacy such as tonalization and expression. Headache caused by cold, cold, fever, etc.

또한 본 발명에 따른 조성물에 맛의 향상을 위해 첨가할 수 있는 흑설탕 (black sugar)은 사탕수수에서 제조하는 함밀당(含蜜糖)의 하나이다. 사탕수수의 즙액을 졸인 후 원심분리기로 당밀을 제거하지 않은 것으로서, 사탕수수의 줄기에서 짜낸 즙액에 석회 등의 청징제(淸澄劑)를 가한 다음 졸인 것이다. 흑설탕은 흰설탕에 비해 정제 단계에서 없어지는 미네랄, 비타민이 풍부할 뿐 아니라, 체내에서 유효한 작용을 하게 된다.In addition, black sugar (black sugar) that can be added to the composition according to the present invention to improve the taste is one of the sugar-containing sugar produced in sugar cane. The molasses of sugar cane is boiled and the molasses is not removed by centrifugal separator. The juice from the stem of sugar cane is added to a juice solution, such as lime, and then boiled. Brown sugar is not only rich in minerals and vitamins that are lost in the refining stage, but also effective in the body.

본 발명에 따른 면역 증강용 조성물에서, 각 생약들은 통상의 방법에 의해 그 유효성분들을 각각 추출하거나, 또는 생약들을 혼합한 후 한꺼번에 추출하고, 필요한 경우 이를 농축건조시켜 분말화한다. 본 발명에 따른 면역 증강용 조성물에서, 각 생약들은 바람직하게는 규정된 중량비로 혼합한 후, 물로 추출하여 얻어진다.In the composition for enhancing immunity according to the present invention, each herbal medicine is extracted by the conventional method, respectively, or after mixing the herbal medicines at once, and if necessary, concentrated and dried to powder them. In the immune enhancing composition according to the present invention, each herbal medicine is preferably obtained by mixing with a prescribed weight ratio and then extracting with water.

본 발명에 따른 면역 증강용 조성물은 바람직하게는 약제학적으로 허용되는 담체를 추가로 함유한다. 본 발명의 조성물 내에서 사용될 수 있는 담체는 약제학적 분야에서 통상적인 것으로, 예를 들면 경구투여용 제제의 경우에는 결합제, 활택제, 붕해제, 부형제, 가용화제, 안정화제 등이 있고, 국소투여용 제제의 경우에는 기제, 부형제, 윤활제, 보존제 등이 있다.The immune enhancing composition according to the present invention preferably further contains a pharmaceutically acceptable carrier. Carriers that can be used in the composition of the present invention are conventional in the pharmaceutical field, for example, in the case of oral preparations, there are binders, lubricants, disintegrants, excipients, solubilizers, stabilizers, and the like. In the case of a solvent preparation, there are a base, an excipient, a lubricant, and a preservative.

본발명에 따른 조성물은 약제학적 분야에서 통상적인 제제, 예를 들면, 정제, 캅셉제, 트로키제, 액제, 현탁제 등의 경구투여용 제제, 주사용 용액 또는 현탁액, 또는 주사 시에 주사용 증류수로 제조하여 사용할 수 있는 즉시 사용형 주사용 건조 분말 등의 형태인 주사용 제제, 연고제, 크림제, 액제 등의 국소적용형 제제 등의 다양한 제제로 제형화할 수 있다. 본 발명에 따른 조성물은 바람직하게는 액제 형태이다. 본발명에 따른 조성물은 더욱 바람직하게는, 활성성분인 생약들의 추출물에 발효 원료를 부가하여 알콜 발효시켜 만드는 주제(酒劑) 형태이다. 발효 원료로는, 알콜 발효에 통상적으로 사용되는 곡물이면 어느 것이나 사용될 수 있는데, 예를 들면, 쌀, 누룩, 효모, 찹쌀, 조 등이다. 발효 원료로는, 특히 쌀, 누룩 및 효모의 혼합물을 사용하는 것이 맛이나 간편성의 면에서 바람직하다.Compositions according to the present invention are conventional formulations in the pharmaceutical field, such as tablets, capsules, troches, solutions, suspensions or the like, oral injectable solutions or suspensions, or distilled water for injection upon injection. It may be formulated into a variety of preparations, such as topical preparations such as injectable preparations, ointments, creams, liquids, etc. in the form of ready-to-use injectable dry powders that can be prepared and used. The composition according to the invention is preferably in liquid form. The composition according to the present invention is more preferably in the form of a subject made by alcohol fermentation by adding fermentation raw materials to extracts of the active ingredients as herbal ingredients. As the fermentation raw material, any grains commonly used for alcoholic fermentation can be used, for example, rice, yeast, yeast, glutinous rice, crude and the like. As the fermentation raw material, it is particularly preferable to use a mixture of rice, yeast and yeast in view of taste and simplicity.

본 발명의 바람직한 구체예에서, 본 발명에 따른 조성물은 감초, 대추, 배, 백출, 생강, 소엽, 진피 및 총백이 1∼4 : 1∼4 : 10∼40 : 3∼9 : 1∼4 : 1∼4 : 2∼6 : 5∼10의 중량비로 포함한다. 또한, 쌀, 누룩 및 효모를 추가로 함유하며 통상의 방법으로 발효시켜 적정 농도의 기능성 주제(酒劑)로 제조하는 것이 바람직하다. 즉, 감초, 대추, 배, 백출, 생강, 소엽, 진피 및 총백이 1∼4 : 1∼4 : 10∼40 : 3∼9 : 1∼4 : 1∼4 : 2∼6 : 5∼10의 중량비로 혼합하여 달이고 농축시켜 얻은 수추출액에, 쌀, 누룩 및 효모를 100∼400 : 20∼100 : 0∼10의 중량비로 혼합한 것을 상기 수추출액의 30∼40 중량%로 가하고 발효시켜 적당한 농도의 주제로 제조한다.In a preferred embodiment of the present invention, the composition according to the present invention has licorice, jujube, pear, baekchul, ginger, lobule, dermis, and baekbaek 1-4: 1-4: 10-40: 3-9: 1-4: It contains in the weight ratio of 1-4: 2-6: 5-10. In addition, it is preferable to further contain rice, yeast and yeast and to ferment by a conventional method to produce a functional concentration of a suitable concentration. That is, licorice, jujube, pear, white peach, ginger, lobule, dermis and total white are 1-4: 1-4: 10-40: 3-9: 1-4: 1-4: 2-6: 5-10 To the water extract obtained by mixing in a weight ratio and decanted, rice, yeast and yeast were mixed at a weight ratio of 100 to 400: 20 to 100: 0 to 10 to 30 to 40% by weight of the water extract and fermented to a suitable concentration. Manufactured with the theme of.

또한 본 발명의 조성물은 감초, 대추, 배, 백출, 생강, 소엽, 진피 및 총백이 1∼4 : 1∼4 : 10∼40 : 3∼9 : 1∼4 : 1∼4 : 2∼6 : 5∼10의 중량비의 혼합물에 쌀 100∼400의 비율로 만든 증미 : 누룩 20∼100: 효모 0∼10의 중량비로 혼합하고 발효시켜 얻은 알콜 추출물도 포함한다.In addition, the composition of the present invention is licorice, jujube, pear, baekchul, ginger, leaflet, dermis and total white 1-4: 1-4: 10-40: 3-9: 1-4: 1-4: 2-6: Also included is an alcohol extract obtained by mixing and fermenting a mixture of 5 to 10 in a weight ratio of rice: 100 to 400 in a ratio of yeast 20 to 100: yeast 0 to 10.

상기 언급한 생약들의 조성비는 반복된 실험결과를 토대로 얻어진 것이며, 각 생약들의 조성비가 그 하한치보다 낮을 경우에는 본 발명의 조성물의 약리효과가 감소하며, 그 상한치보다 높을 경우에는 각각의 성분의 약리효과가 감소될 수 있어 본 발명의 조성물의 상승작용 및 협동작용이 저하될 우려가 있다.The composition ratios of the above-mentioned herbal medicines are obtained based on the repeated experimental results, and when the composition ratio of each herbal medicine is lower than the lower limit, the pharmacological effect of the composition of the present invention is reduced, and when higher than the upper limit, the pharmacological effect of each component Can be reduced so that the synergy and coordination of the composition of the present invention is reduced.

본 발명의 조성물은 면역력 증강을 통한 감기 예방 또는 치료 보조제 등으로서 사용될 수 있으며, 이러한 약리효과는 하기 실험예 1 내지 3으로부터 확인된다. 본 발명에 따른 조성물은 면역 담당세포로부터 사이토카인 및 화학적 매개물질의 생성을 조절하여 국소 또는 전신의 면역능을 증강하는 것으로 추정된다.The composition of the present invention can be used as an adjuvant for preventing or treating colds through enhanced immunity, and such pharmacological effects are confirmed from Experimental Examples 1 to 3 below. The composition according to the present invention is estimated to enhance the local or systemic immune capacity by regulating the production of cytokines and chemical mediators from immune cells.

본 발명의 조성물의 바람직한 일예를 들면, 감초 10∼40g, 대추 10∼40g, 배 100∼400g, 백출 30∼90g, 생강 10∼40g, 소엽 10∼40g, 진피 20∼60g, 총백 50∼100g 및 흑설탕 10∼40g에 물 6,000 ㎖를 붓고, 약 2.5 시간동안 달여 약 4,000 ㎖로 농축시켜 추출액을 얻고, 별도로 쌀 1∼4kg으로 만든 증미, 누룩 0.2∼1kg 및 효모 0∼0.1kg을 균일하게 혼합한 것에 상기 추출액을 붓고, 20∼27℃에서 5∼10일간 발효시키고 여과하여 주제를 제조한 후 정제수를 추가하여 3,000 ㎖로 조절한다.Preferred examples of the composition of the present invention include licorice 10-40g, jujube 10-40g, pear 100-40g, white 100-90g, ginger 10-40g, leaflet 10-40g, dermis 20-60g, total white 50-100g and Pour 6,000 ml of water into 10 to 40 g of brown sugar, decoction for about 2.5 hours, concentrate to about 4,000 ml to obtain an extract, and mix uniformly the steamed yeast, 0.2-1 kg of yeast and 0-0.1 kg of yeast, which are made separately from 1-4 kg of rice The extract was poured into the solution, fermented at 20 to 27 ° C. for 5 to 10 days, filtered to prepare a subject, and then purified water was adjusted to 3,000 ml.

본 조성물의 통상적인 1회 투용량은 체중 1 kg당 0.1∼5.0 ㎖, 바람직하게는 1.0∼2.0 ㎖이며, 이를 1일 3회 복용한다. 예를들어, 체중 60 kg인 성인의 경우, 1회 6∼300㎖씩 1일 3회 복용한다. 이러한 용량으로 복용시 상기 제조물은 약8∼15일 분량이 된다. 그러나, 본 발명의 조성물은 환자의 체중, 연령, 성별, 병증의 경중정도와 소화상태에 따라 복용량을 적의 증감할 수 있다. 기타 제제에 있어서도 상기 액제 복용량을 고려하여 산출된 적정량을 경구 또는 비경구 투여할 수 있다. 빠르면 복용 후 2∼3일 후부터 증상의 경감효과를 나타낼 수 있으나 개인차가 있다. 효과가 나타나기 시작한 후 약 1개월간 지속적으로 복용한다.A typical single dose of the composition is 0.1-5.0 ml, preferably 1.0-2.0 ml per kg body weight, which is taken three times a day. For example, for adults weighing 60 kg, take 6 to 300 ml once three times a day. When taken at this dose, the preparation is about 8 to 15 days old. However, the composition of the present invention can be appropriately increased or decreased the dose depending on the weight, age, sex, severity of the patient and the digestive state. In other formulations, an appropriate amount calculated in consideration of the liquid dosage can be administered orally or parenterally. As early as two to three days after taking the symptoms of the symptoms can be reduced, but there are individual differences. Take it for about a month after the effect starts.

이하, 본 발명을 하기 실시예에 의하여 보다 구체적으로 설명하지만, 이들에 의해 본 발명의 범위가 어떤 식으로든 제한되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following Examples. The scope of the present invention is not limited in any way.

실시예 1: 액제의 제조Example 1 Preparation of Liquid

감초 4g, 대추 4g, 배 40g, 백출 6g, 생강 4g, 소엽 4g, 진피 6g 및 총백 10g의 혼합물에 물 1,000 ㎖를 붓고 약 2 시간동안 달인 후, 약 150 ㎖로 농축시켜 액제를 제조하였다.Licorice 4g, jujube 4g, pear 40g, baekchul 6g, ginger 4g, lobule 4g, dermis 6g and a total of 10g poured 1,000ml of water, decoction for about 2 hours, concentrated to about 150ml to prepare a liquid formulation.

실시예 2: 주제(酒劑)의 제조Example 2: Preparation of Moisture

감초 40g, 대추 80g, 배 800g, 백출 120g, 생강 80g, 소엽 40g, 진피 60g, 총백 200g, 흑설탕 80g의 혼합물에 물 6,000 ㎖를 붓고 약 2.5 시간동안 달인 후, 약 4,000 ㎖로 농축시켜 추출액을 얻고, 이 추출액에, 별도로 쌀 2 kg으로 만든 증미, 누룩 1kg 및 효모 50g을 균일하게 혼합한 것을 상기 추출액의 30중량%로 붓고, 20∼27℃에서 7 일간 발효시켰다. 발효액을 여과하여 액상부분과 고형부분을 분리하고 55∼60℃로 가열한후 여액에 정제수를 가하여 3,000 ㎖로 조절하여 주제를 제조하였다.Licorice 40g, jujube 80g, pear 800g, white roe 120g, ginger 80g, lobule 40g, dermis 60g, total white 200g, brown sugar 80g pour 6,000 ml of water, decoction for about 2.5 hours, concentrated to about 4,000 ml to obtain an extract To the extract, a mixture of steamed rice, yeast 1 kg and yeast 50 g, which was separately made from 2 kg of rice, was poured into 30% by weight of the extract and fermented at 20 to 27 ° C. for 7 days. The fermentation broth was filtered to separate the liquid and solid portions, heated to 55-60 ° C., and purified water was added to the filtrate.

실험예 1: 독성 및 부작용 확인시험Experimental Example 1: Toxicity and Side Effects Identification Test

실시예 1에서 제조한 액제를 사람에게 투여하는 용량비율(체중 1 kg당 1∼2 ㎖의 투여량)의 각각 1 배(2 ㎖/kg), 5 배(10 ㎖/kg) 및 10 배(20 ㎖/kg) 투여량으로 성체 흰쥐 30마리에 90일동안 경구투여한 후, 30일 이상 매일 관찰하였다. 그 결과, 모든 실험군에서 외견상 생리적 이상은 물론 해부학적 소견상 어떠한 이상도 발견되지 않았다.1 times (2 mL / kg), 5 times (10 mL / kg), and 10 times the dose ratio (dose of 1-2 ml per kg of body weight) of administering the liquid preparation prepared in Example 1 to human 20 ml / kg) was administered orally to 30 adult rats for 90 days and then observed daily for more than 30 days. As a result, no abnormalities were found in all experimental groups as well as in physiological abnormalities.

이에, 본 발명자들은 20세 이후 성인 남녀 지원자를 대상으로, 상기 액제의 적정 투여량과 투여방법을 연구하였으며, 그 결과, 상기의 표준 약용량을 결정한 후 환자의 연령 등에 따라 적의 증감하여 투여하였다. 이렇게 투여된 사람의 소수에서 위장관 불쾌감, 일시적 명현현상 또는 주취 현상이 나타난 것을 제외하고는 다른 어떤 심각한 국소 또는 전신적인 부작용이 확인되지 않았으며, 위장관 불쾌감도 약용량을 1/2 내지 2/3로 감량한 후부터는 현저하게 소멸되었다.Accordingly, the present inventors studied the appropriate dosage and administration method of the liquid formulation for adult male and female volunteers after 20 years of age. Except for the appearance of gastrointestinal discomfort, transient phenomena or intoxication in a small number of people, no serious local or systemic side effects have been identified, and the gastrointestinal discomfort level is 1/2 to 2/3. After losing weight, it disappeared remarkably.

실험예 2: 인터페론-감마 생성 증가효과Experimental Example 2 effect of increasing interferon-gamma production

인터페론-감마는 TH1세포가 분비하는 사이토카인으로서 면역기능에 중요한 역할을 하며 이것의 증가는 면역능 증가의 지표로서 이해될 수 있다. TH1세포의 세포주의 하나인 몰트-4를 배양하여 2 ×105cell/well로 세포를 심고(seeding) 30분간 안정화시켰다. 여기에 실시예 2의 주제를 동결건조하여 분말화 한 시료(0.01mg/㎖, 0.1mg/㎖, 1.0mg/㎖ 의 농도) 및 및 기타 자극원, 예컨데 피토헤마글루티닌(Phytohaemaglutinin: PHA) 20㎍/ml 을 처리하고, 24시간후에 인터페론-감마의 생성정도를 엘라이자 방법을 이용하여 측정하였고, 그 결과를 도 1에 나타내었다.Interferon-gamma is a cytokine secreted by T H 1 cells and plays an important role in immune function and its increase can be understood as an indicator of increased immune function. Malt-4, a cell line of T H 1 cells, was cultured and seeded at 2 × 10 5 cell / well and stabilized for 30 minutes. Samples powdered by lyophilizing the subject of Example 2 (concentrations of 0.01 mg / ml, 0.1 mg / ml, 1.0 mg / ml) and other stimulants, such as Phytohaemaglutinin (PHA) After 20 hr / ml treatment, the production of interferon-gamma was measured using the ELISA method after 24 hours, and the results are shown in FIG. 1.

도 1과 같이, 본 발명의 조성물은 농도 의존적으로 인터페론-감마의 생성량을 증가시켰다.As shown in Figure 1, the composition of the present invention increased the amount of interferon-gamma produced in a concentration-dependent manner.

실험예 3: 인터루킨-2의 생성능력 측정Experimental Example 3: Measurement of the production capacity of interleukin-2

인터페론-감마와 함께 인터루킨-2도 TH1세포가 분비하는 사이토카인으로서 면역기능에 중요한 역할을 하며, 이것의 증가 역시 면역능 증가의 지표로서 이해될 수 있다. TH1세포의 세포주인 몰트-4를 배양하여 2 ×105cell/well로 세포를 심고 30분간 안정화시켰다. 여기에 실시예 2의 주제를 동결건조하여 분말화 한 시료(0.01mg/㎖, 0.1mg/㎖, 1.0mg/㎖)를 처리하고, 24시간후에 인터루킨-2의 생성정도를 엘라이자 방법을 이용하여 측정하고, 그 결과를 표 1에 나타내었다.In addition to interferon-gamma, interleukin-2 also plays an important role in immune function as a cytokine secreted by T H 1 cells, and its increase can also be understood as an indicator of increased immune function. Malt-4, a cell line of T H 1 cells, was cultured and seeded with 2 × 10 5 cell / well and stabilized for 30 minutes. The subject of Example 2 was lyophilized and treated with powdered samples (0.01 mg / ml, 0.1 mg / ml, 1.0 mg / ml), and the production of interleukin-2 was determined after 24 hours using the ELISA method. And the results are shown in Table 1.

본 발명의 조성물의 농도(mg/ml)Concentration of Compositions of the Invention (mg / ml) IL-2(ng/ml)IL-2 (ng / ml) 00 0.103 ±0.010.103 ± 0.01 0.10.1 0.231 ±0.040.231 ± 0.04 1One 0.354 ±0.07* 0.354 ± 0.07 *

상기 표 1과 같이, 본 발명의 조성물은 인터루킨-2의 생성량을 현저히 증가시켰다.As shown in Table 1, the composition of the present invention significantly increased the amount of interleukin-2 produced.

실험예 4: 히스타민 분비 억제 효과Experimental Example 4: Histamine secretion inhibitory effect

초기 감기 증상 중 대표적인 것은 비염이나 비색 등과 같은 일종의 알레르기성 반응이다. 이러한 증상의 대증 치료 수단로서 스테로이드성 항히스타민제가 많이 활용된다. 그러나 이러한 항히스타민제는 많은 부작용이 따르며, 효과 또한 일시적이다. 따라서 면역증강을 통한 감기 예방 및 치료보조제로서 히스타민 분비 억제 효과는 중요한 지표가 될 수 있다. 따라서 본 발명의 조성물로 비만세포주에 대한 히스타민 억제 효과를 관찰하였다. 흰쥐를 에테르로 마취시킨 후 0.1% 젤라틴(gelatin)을 함유한 티로드(Tyrode) 버퍼 B (1mM MgCl2, 1.8mM CaCl2, 137mM NaCl, 12mM NaHCO3, 2.7mM KCl, 0.2mM NaH2PO4, 5.5mM glucose) 약 20 ml를 복강내에 주입하고 30초간 복벽을 가볍게 맛사지한 후, 복벽 중앙선을 조심스럽게 절개하여 복강세포를 함유한 세척액을 파스퇴르 피펫으로 채취하였다. 복강세포를 150 ×g로 10분간씩 3회 반복하여 원심분리한 후, 상층 부유액을 버리고 동일 티로드 버퍼 B로 재부유시켰다. 이 세포부유액중 비만세포는 22.5%(w/v) 메트리자마이드 (metrizamide)를 이용하여 분리 정제하였다. 즉 티로드 버퍼 B 1 ml에 현탁시킨 복강세포(6∼9 ×107)에 22.5% (w/v) 메트리자마이드(농도 1.120 g/ml)를 중첩시켜, 400 ×g에서 15분동안 상온에서 원심분리하였다. 완충액과 메트리자마이드 접촉면의 세포는 수집하여 버리고, 펠렛의 세포를 티로드 버퍼 B 1 ml에 재부유시켰다.99% 이상 순도의 복강 비만세포를 얻기 위해 이 과정을 반복하였다.One of the most common cold symptoms is an allergic reaction, such as rhinitis or coloritis. Steroidal antihistamines are widely used as a symptomatic treatment for these symptoms. However, these antihistamines have many side effects and their effects are temporary. Therefore, the inhibitory effect of histamine secretion as an adjuvant against colds and treatment through immunity can be an important indicator. Therefore, the histamine inhibitory effect on the mast cell line was observed with the composition of the present invention. Rats were anesthetized with ether, followed by Tyrode buffer B (1 mM MgCl 2 , 1.8 mM CaCl 2 , 137 mM NaCl, 12 mM NaHCO 3 , 2.7 mM KCl, 0.2 mM NaH 2 PO 4 ) containing 0.1% gelatin. , 5.5mM glucose) was injected intraperitoneally, and the abdominal wall was lightly massaged for 30 seconds. Then, the abdominal wall center line was carefully cut and a washing solution containing peritoneal cells was collected with a Pasteur pipette. The peritoneal cells were centrifuged at 150 × g for 3 min each time, and the supernatant was discarded and resuspended with the same T-load buffer B. The mast cells in the cell suspension were separated and purified using 22.5% (w / v) metrizamide. In other words, 22.5% (w / v) methazamide (concentration 1.120 g / ml) was superimposed on peritoneal cells (6 to 9 x 10 7 ) suspended in 1 ml of T-load buffer B, and then heated at 400 x g for 15 minutes. Centrifugation at. Cells at the buffer and methazamide contact surfaces were collected and resuspended in pellets of 1 ml of T-load buffer B. This procedure was repeated to obtain peritoneal mast cells with greater than 99% purity.

이렇게 얻어진 비만세포를 96 웰에 각각 부가하고, 실시예 2에 따른 주제를 분말화시킨 시료를 0.01, 0.1 및 1 mg/ml의 농도로 3 개씩 각 웰에 첨가시켰다. 대조구로서는 증류수를 첨가시켰다. 이후 compound 48/80 6㎍/ml 양만큼 각 웰에 부가시켜 히스타민 분비를 유도하였다. 37℃에서 20분 경과 후, 분비된 히스타민 양을 측정하였다. 히스타민 량의 측정을 위해 다음과 같은 과정을 거쳤다.The mast cells thus obtained were added to 96 wells, and three samples, each of which was powdered with a subject according to Example 2, were added to each well at concentrations of 0.01, 0.1 and 1 mg / ml. Distilled water was added as a control. Then, the amount of compound 48/80 6 ㎍ / ml was added to each well to induce histamine secretion. After 20 minutes at 37 ° C., the amount of histamine released was measured. In order to measure the amount of histamine, the following procedure was carried out.

상기 각 웰 내의 시료를 3000 rpm으로 5분간 원심분리 한 후 에펜돌프 튜브에 상등액 500 ㎕를 넣고 0.1N-HCI 450 ㎕, 60% 과염소산 용액 50 ㎕를 넣고 혼합 후, 원심분리(1,500 rpm, 20분)하여 그 상층액 800 ㎕를 5 N-NaOH 용액 500 ㎕, 증류수 3 ml, n-부탄올 10 ml 및 NaCl 1.2 g을 혼합한 시험관에 넣고, 진탕 후 원심분리(2,000 rpm, 10분)하였다. 부탄올층 8 ml를 50 ml 시험관에 넣고 0.1 N-HCI 용액 3 ml, n-헵탄 10 ml를 가하여 진탕 후 원심분리(2,000 rpm, 10 분)하였다. 여기에서 얻어진 수층 2 ml에 1 N-NaOH 용액 400 ㎕와 1%o-프탈디알데하이드 (o-phthaldialdehyde) 용액 100 ㎕를 넣고, 혼합 후 2분 동안 방치하여 스펙트로플루오르미터(spectrofluormeter)(λex = 360nm, λex = 440 nm)로 형광도를 측정하여 분비된 히스타민 량의 측정하였고, 그 결과를 도 2에 나타내었다.Centrifuge the sample in each well for 5 minutes at 3000 rpm, and then put 500 μl of the supernatant into the eppendorf tube, add 450 μl of 0.1N-HCI, 50 μl of 60% perchloric acid solution, and mix and centrifuge (1,500 rpm, 20 minutes). The supernatant was added to 800 µl of a 5 N-NaOH solution, 3 ml of distilled water, 10 ml of n-butanol, and 1.2 g of NaCl, followed by centrifugation (2,000 rpm, 10 minutes) after shaking. 8 ml of butanol layer was placed in a 50 ml test tube, and 3 ml of 0.1 N-HCI solution and 10 ml of n-heptane were added thereto, followed by centrifugation (2,000 rpm, 10 minutes). To the aqueous layer obtained here with 2 ml 1 N-NaOH solution 400 ㎕ 1% o - au taldi aldehyde (o -phthaldialdehyde) into a solution of 100 ㎕, allowed to stand for two minutes after mixing the fluorine-meter spectrometer (spectrofluormeter) (λex = 360nm , λex = 440 nm) was measured to measure the amount of histamine secreted, and the results are shown in FIG.

도 2와 같이, 본 발명의 조성물은 히스타민 억제효과가 우수하였다.As shown in Figure 2, the composition of the present invention was excellent in histamine inhibitory effect.

상기와 같이, 본 발명의 조성물은 인터루킨-2 및 인터페론-감마 생성증가를 갖고 있음을 알 수 있다. 인터루킨-2와 인터페론-감마(IFN-γ)등의 생성능력은 면역증강효과와 직간접적으로 연관된다. 또한 본 발명의 조성물은 히스타민의 분비를 억제하는 효과도 가짐을 알 수 있다. 면역증강 효과로 기대할 수 있는 다양한 긍정적 기능 중에는 감기의 예방효과도 포함된다. 히스타민 분비 억제 효과는 초기감기의 제 증상을 완화하는 역할을 할 수 있다.As described above, it can be seen that the composition of the present invention has an increase in interleukin-2 and interferon-gamma production. The ability to produce interleukin-2 and interferon-gamma (IFN- [gamma]) is directly or indirectly related to the immune enhancing effect. In addition, it can be seen that the composition of the present invention also has an effect of inhibiting the release of histamine. Among the many positive functions that can be expected from immune-boosting effects include the prevention of colds. The inhibitory effect of histamine secretion may play a role in alleviating the symptoms of early cold.

따라서 본 발명의 조성물은 여러 가지 유해 환경에 노출되어 면역력이 저하된 현대 산업사회에서 면역력 저하에 따른 질환, 특히 감기의 예방과 초기 감기의 치료 또는 치료보조제로서 유용하게 사용될 수 있다.Therefore, the composition of the present invention can be usefully used in the prevention of diseases caused by lowering immunity, especially cold and treatment or treatment aid of early cold in modern industrial society in which immunity is lowered by exposure to various harmful environments.

Claims (7)

감초, 대추, 배, 백출, 생강, 소엽, 진피 및 총백 추출물을 함유하는 면역 증강용 조성물.Immunity-enhancing composition containing licorice, jujube, pear, baekchul, ginger, lobule, dermis and baekbaek extract. 제1항에 있어서, 상기 추출물은 물로 추출하여 얻은 수추출물인 조성물.The composition of claim 1, wherein the extract is a water extract obtained by extraction with water. 제1항 또는 제2항에 있어서, 감초, 대추, 배, 백출, 생강, 소엽, 진피 및 총백이 1∼4 : 1∼4 : 10∼40 : 3∼9 : 1∼4 : 1∼4 : 2∼6 : 5∼10의 중량비로 혼합된 조성물.The licorice, jujube, pear, white extract, ginger, lobule, dermis and total white are 1-4: 1-4: 10-40: 3-9: 1-4: 1-4: A composition mixed at a weight ratio of 2 to 6: 5 to 10. 제1항 또는 제2항에 있어서, 흑설탕을 더 포함하는 조성물.The composition of claim 1 or 2, further comprising brown sugar. 제2항에 있어서, 수추출물에 추가로 발효 원료를 첨가해 발효시켜 얻어지는 주제(酒劑) 형태인 조성물.The composition according to claim 2, wherein the composition is in the form of a main ingredient obtained by adding fermentation raw material to the water extract and fermenting the same. 제5항에 있어서, 발효 원료는 1∼4 : 0.2∼1 : 0∼0.1의 중량비로 혼합된 쌀, 누룩 및 효모의 혼합물인 조성물.The composition of claim 5, wherein the fermentation raw material is a mixture of rice, yeast and yeast mixed in a weight ratio of 1 to 4: 0.2 to 1: 0 to 0.1. 감초, 대추, 배, 백출, 생강, 소엽, 진피 및 총백 혼합물의 수추출물에 쌀,누룩 및 효모의 혼합물을 첨가하고, 발효시키는 것을 특징으로 하는 제5항의 조성물의 제조방법.A method of producing the composition of claim 5, wherein a mixture of rice, yeast and yeast is added to the water extracts of licorice, jujube, pear, baekchul, ginger, lobule, dermis and ginseng mixture.
KR10-2001-0086846A 2001-12-28 2001-12-28 Composition for immune enhancement KR100443401B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2001-0086846A KR100443401B1 (en) 2001-12-28 2001-12-28 Composition for immune enhancement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2001-0086846A KR100443401B1 (en) 2001-12-28 2001-12-28 Composition for immune enhancement

Publications (2)

Publication Number Publication Date
KR20030056582A true KR20030056582A (en) 2003-07-04
KR100443401B1 KR100443401B1 (en) 2004-08-09

Family

ID=32214766

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-0086846A KR100443401B1 (en) 2001-12-28 2001-12-28 Composition for immune enhancement

Country Status (1)

Country Link
KR (1) KR100443401B1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100939658B1 (en) * 2008-02-28 2010-02-03 보령메디앙스 주식회사 Mixture extract of aged gallic, Melonis PedicellusCucumis melo var. makuwa MAKINO and Allii RadixAllium fistulosum L.
KR101134781B1 (en) * 2009-12-30 2012-04-13 인제대학교 산학협력단 Composition comprising an the extract of Allium fistulosum L. for preventing and treating diabetes mellitus
KR101306950B1 (en) * 2011-04-01 2013-09-09 서범구 Composition for food using medicinal herbs and seonokgyun and manufacturing method thereof
KR102252130B1 (en) * 2020-08-03 2021-05-18 주식회사 톱스톡 A composition for increasing functions of immune comprising natural extracts
CN113171373A (en) * 2021-04-28 2021-07-27 河北科技师范学院 Preparation method and application of avocado polysaccharide
KR102331255B1 (en) * 2021-06-04 2021-12-02 농업회사법인 꿀작 주식회사 Method for preparing of ginger syrup and ginger syrup prepared thereby

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103536743A (en) * 2013-09-24 2014-01-29 李建奎 Traditional Chinese medicine formula of cold dispelling powder
KR101935689B1 (en) 2017-09-12 2019-04-04 에스케이바이오랜드 주식회사 Composition comprising mixture extract of jujube, licorice and platycodon for enhancing immune response

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100247323B1 (en) * 1997-11-05 2000-04-01 박진수 An extract of natural herbal medicine materials radiating active bio-energy wave of superconductivity
KR100282165B1 (en) * 1998-06-09 2001-02-15 문명현 Medicinal manufacturing method using herbal medicine
KR100371601B1 (en) * 2000-06-09 2003-02-11 천현욱 Making method of health tea
KR20020013134A (en) * 2000-08-11 2002-02-20 박찬우 Immune Modulator and food containing the same
KR20010000342A (en) * 2000-09-18 2001-01-05 박증국 Chinese herb medicine composition and pharmaceutical preparation thereof
KR20020025433A (en) * 2000-09-29 2002-04-04 문형대 Composition And Complex For Enhancing The Biological Function of Animals
KR100382183B1 (en) * 2001-07-26 2003-05-09 주식회사 자광 Pharmaceutical composition for increasing the production of nitric oxide and IFN-γ, and process for the preparation thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100939658B1 (en) * 2008-02-28 2010-02-03 보령메디앙스 주식회사 Mixture extract of aged gallic, Melonis PedicellusCucumis melo var. makuwa MAKINO and Allii RadixAllium fistulosum L.
KR101134781B1 (en) * 2009-12-30 2012-04-13 인제대학교 산학협력단 Composition comprising an the extract of Allium fistulosum L. for preventing and treating diabetes mellitus
KR101306950B1 (en) * 2011-04-01 2013-09-09 서범구 Composition for food using medicinal herbs and seonokgyun and manufacturing method thereof
KR102252130B1 (en) * 2020-08-03 2021-05-18 주식회사 톱스톡 A composition for increasing functions of immune comprising natural extracts
CN113171373A (en) * 2021-04-28 2021-07-27 河北科技师范学院 Preparation method and application of avocado polysaccharide
KR102331255B1 (en) * 2021-06-04 2021-12-02 농업회사법인 꿀작 주식회사 Method for preparing of ginger syrup and ginger syrup prepared thereby

Also Published As

Publication number Publication date
KR100443401B1 (en) 2004-08-09

Similar Documents

Publication Publication Date Title
KR20120133133A (en) Composition for Prevention or Treatment of Respiratory Disease Comprising Herbal Extract and Fermentation Product thereof with Lactic acid Bacteria
CN103585433B (en) Traditional Chinese medicine composition for treating oral ulcer
EP3566702B1 (en) Pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy, comprising baicalein as active ingredient
KR100443401B1 (en) Composition for immune enhancement
CN102526546A (en) Chinese medicinal composition and preparation and preparation method thereof
KR101826737B1 (en) A composition containing herbs extract, and manufacturing method of the same
CN101933973B (en) Medicament composition for preventing and treating liver damage
CN115487280B (en) Traditional Chinese medicine composition for dispelling effects of alcohol, protecting liver and promoting liver regeneration as well as preparation and preparation method thereof
KR100477959B1 (en) A composition comprising the extract of herb medicines for enhancing immunity and a medical wine using the composition
KR20020012436A (en) Healthy food composition for preventing and treatmenting constipation
CN113499381B (en) Application of traditional Chinese medicine composition and/or pharmaceutical preparation containing traditional Chinese medicine composition in resisting influenza virus
CN111588801B (en) Traditional Chinese medicine dispersible granule for preventing livestock and poultry epidemic diseases and preparation method thereof
CN114404517A (en) Composition for gout and reducing uric acid and application and preparation method thereof
KR101141191B1 (en) Functional food composition and pharmaceutical composition for the prevention and alleviation of allergy symptoms
CN113499383B (en) Application of traditional Chinese medicine composition and/or pharmaceutical preparation containing traditional Chinese medicine composition in preparation of anti-inflammatory drugs or immunoregulation drugs
KR102517886B1 (en) Korean Medicine Composition Comprising Herbal Mixture for Improving Liver Function
Fossum Assessment report on Sambucus nigra L., fructus
CN111759901B (en) Traditional Chinese medicine composition for treating functional abdominal pain of children and preparation method thereof
CN113398189B (en) Application of traditional Chinese medicine composition in preparation of anti-influenza virus medicine
Rose Herbal and nutritional support for the immune system
CN113491726A (en) Traditional Chinese medicine composition for preventing and treating pneumonia and improving disease resistance of organism and application thereof
CN104306652A (en) Traditional Chinese medicine composition for treating cough and preparation method and application
KR20240111655A (en) A therapeutic formula for stomach disorders, comprising Atractylodis Rhizoma and oat
CN110624005A (en) Composition for preventing and treating chemical liver injury and preparation method and application thereof
KR20210122367A (en) Compositions containing Acanthopanax sessiliflorum, Fagopyri Semen and Chaenomelis Fructus extracts for the Improvement of Allergic Rhinitis and Manufacturing Method Thereof

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070709

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee